Assertio Holdings (ASRT) Cash from Investing Activities (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Cash from Investing Activities came in at $15.1 million in Q1 2026, up 614.82% year-on-year from $2.1 million in Q1 2025, and up 789.35% quarter-over-quarter from $1.7 million in Q4 2025.
Assertio Holdings (ASRT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Cash from Investing Activities across 8 years of filings, most recently posting $15.1 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $15.1 million, up 614.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (up 111.68% YoY), and the FY2025 annual result was -$12.0 million, up 75.49% from the prior year.
- Cash from Investing Activities came in at $15.1 million for Q1 2026 at Assertio Holdings, up from $1.7 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $15.1 million in Q1 2026 to a low of -$43.3 million in Q2 2024.
- The 5-year median for Cash from Investing Activities is -$553500.0 (2022), against an average of -$5.3 million.
- Across the five-year window, Cash from Investing Activities surged 1216.98% in 2023 and tumbled 6062.16% in 2024, its largest moves.
- Assertio Holdings' Cash from Investing Activities stood at -$25.8 million in 2022, then soared by 99.07% to -$239000.0 in 2023, then soared by 567.78% to $1.1 million in 2024, then surged by 51.97% to $1.7 million in 2025, then soared by 789.35% to $15.1 million in 2026.
- The last three Cash from Investing Activities figures came in at $15.1 million (Q1 2026), $1.7 million (Q4 2025), and -$3.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.45 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 25.99 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | 15.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.11 Mn |
| Mar 31, 2026 | 15.11 Mn |
| Dec 31, 2025 | 1.70 Mn |
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | -3.81 Mn |
| Sep 30, 2025 | -3.81 Mn |
| Jun 30, 2025 | -6.94 Mn |
| Jun 30, 2025 | -6.94 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Jun 30, 2024 | -43.32 Mn |
| Jun 30, 2024 | -43.32 Mn |
| Dec 31, 2023 | -239,000.00 |
| Dec 31, 2023 | -239,000.00 |
| Sep 30, 2023 | 4.14 Mn |
| Sep 30, 2023 | 4.14 Mn |